Uticaj riboflavina i ultravioletnog zračenja na proteine plazme – protein S i alfa 2-antiplazmin – u odnosu na vreme primene
Sažetak
Uvod/Cilj. Pažljivim izborom davalaca i korišćenjem visoko osetljivih „skrining“ testova za detekciju uzročnika infekcija koje se mogu preneti putem transfuzije (TTI), krv je postala veoma bezbedan produkt u odnosu TTI. Međutim, zbog postojanja perioda „prozora“ tokom kojeg se ovi „markeri“ ne mogu detektovati, kao i pojave novih patogena, rizik je i dalje prisutan. Uvođenjem tehnologije za redukciju patogena (PRT) ostvaruje se proaktivan pristup u poboljšanju bezbednosti krvi. Oštećenjem nukleinskih kiselina, PRT selektivno inaktivira patogene i leukocite. Nažalost, tokom ovog procesa se u određenom stepenu oštećuju i proteini plazme. Cilj rada je bio da se utvrdi postojanje razlika u efektu PRT na protein S (PS) i α2-antiplazmin (α2AP) u zavisnosti od vremena inaktivacije: ukoliko se plazma inaktivira odmah po izdvajanju iz jedinice krvi (pre zamrzavanja) ili ako se inaktivira naknadno, posle zamrzavanja/odmrzavanja. Metode. Krv dobrovoljnih davalaca je bila prikupljena u sistem četvorostrukih kesa, centrifugirana i razdvojena na produkte. Kontrolna plazma je bila najpre inaktivisana Mirasol® PRT sistemom i, potom, zamrznuta. Plazma eksperimentalne grupe je bila odmah zamrznuta, a nakon četiri meseca odmrznuta i inaktivisana. Aktivnost PS i α2AP je bila ispitivana u uzorcima plazme posle separacije, inaktivacije i odmrzavanja. Rezultati. Analizom rezultata aktivnosti PS i α2AP utvrđeno je da nije bilo statistički značajne razlike između inicijalnih uzoraka. Nakon inaktivacije i zamrzavanja/odmrzavanja postojao je trend pada aktivnosti ovih proteina u obe grupe, ali statistički značajna razlika između kontrolne i eksperimentalne grupe nije ustanovljena. Zaključak. Nije postojala statistički značajna razlika između vrednosti aktivnosti PS i α2AP nakon inaktivacije pre zamrzavanja, odnosno posle zamrzavanja/odmrzavanja, što ukazuje da uskladištene jedinice plazme mogu biti sigurno i efikasno inaktivisane neposredno pre kliničke upotrebe, u skladu sa krvnom grupom primaoca.
Reference
Harmening D. Modern Blood Banking & Transfusion Practices. 6th ed. Philadelphia: Davis Company; 2012. p. 365‒7.
Fung M. Technical Manual 19th ed. Bethesda: AABB, 2017. p. 518.
Kitchen C, Alving B, Kessler C. Consultative Hemostasis and Thrombosis. Philadelphia, Pennsylvania: Elsevier Science; 2002. p. 183.
Rodak B, Fritsma G, Keohane E. Hematology. St. Louis, Mo: Elsevier Saunders; 2012. p. 643.
McCullough J. Pathogen inactivation: a new paradigm for preventing transfusion-transmitted infections. Am J Clin Pathol 2007; 128(6): 945–55.
Klein HG, Glynn SA, Ness PM, Blajchman MA. NHLBI Working Group on Research Opportunities for the Pathogen Reduction/Inactivation of Blood Components. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion 2009; 49(6): 1262‒8.
Pelletier JP, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006; 19(1): 205–42.
Elikaei A, Hosseini SM, Sharifi Z. Inactivation of model viruses and bacteria in human fresh frozen plasma using riboflavin and long wave ultraviolet rays. Iran J Microbiol 2017; 9(1): 50‒4.
Jocic M, Trkuljic M, Jovicic D, Borovcanin N, Balint B. Inactivation efficacy of Mirasol PRT in platelet concentrates using bacteria contamination model. Vojnosanit Pregl 2011; 68(12): 1041–6. (Serbian)
Goodrich RP, Doane S, Reddy HL. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38(1): 20–30.
Cicchetti A, Berrino A, Casini M, Codella P, Facco G, Fiore A, et al. Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use. Blood Transfus 2016; 14(4): 287‒386.
Stanojkovic Z, Balint B, Antic A, Todorovic M, Ostojic G, Pavlovic M. Clinical efficacy of riboflavin and ultraviolet light inactivated fresh frozen plasma evaluated with INR-quantification. Transfus Apher Sci 2012; 47(1): 33‒7.
Keil SD, Ragan I, Yonemura S, Hartson L, Dart NK, Bowen R. Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment. Vox Sang 2020; 115(6): 495‒501.
Yonemura S, Doane S, Keil S, Goodrich R, Pidcoke H, Cardoso M. Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology. Blood Transfus 2017; 15(4): 357‒64.
Dahlbäck B. Vitamin K-Dependent Protein S: Beyond the Protein C Pathway. Semin Thromb Hemost 2018; 44(2): 176‒84.
Fearon A, Pearcy P, Venkataraman S, Shah P. Protein S Deficiency and Arterial Thromboembolism: A Case Report and Review of the Literature. J Hematol 2019; 8(1): 37‒9.
Carpenter SL, Mathew P. α2 -Antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 2008; 14: 1250–4.
Lee KN, Lee CS, Tae WC, Jackson KW, Christiansen VJ, McKee PA. Crosslinking of alpha 2-antiplasmin to fibrin. Ann N Y Acad Sci. 2001; 936: 335‒9.
Balint B, Pavlovic M, Todorovic M, Jevtic M, Ristanovic E, Ignjatovic L. The use of original ex vivo immunoadsorption and "multi-manner" apheresis in ABO/H-mismatched kidney transplants - A phase II clinical study. Transfus Apher Sci 2010; 43(2): 141‒8.
Marschner S, Goodrich R. Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light. Transfus Med Hemother 2011; 38(1): 8–18.
Alter HJ. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008; 22(2): 97‒102.
Goodrich RP, Platz MS. The design and development of selective, photoactivated drugs for sterilization of blood products. Drugs Future 1997; 22: 159–71.
Kasai H, Yamaizumi Z, Yamamoto F, Bessho T, Nishimura S, Berger M, et al. Photosensitized formation of 8-hydroxyguanine (7,8-dihydro-8-oxoguanine) in DNA by riboflavin. Nucleic Acids Symp Ser 1992; (27): 181‒2.
Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 15‒21.
Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011; 100(2): 169–78.
Balint B, Jovicic-Gojkov D, Todorovic-Balint M, Subota V, Pavlovic M, Goodrich R. Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment – A comparative study. Transf Apheres Sci 2013; 49(3): 434‒9.
Smith J, Rock G. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion 2010; 50(4): 926–31.
Hornsey VS, Drummond O, Morrison A, McMillan L, MacGregor IR, Prowse CV. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009; 49(10): 2167–72.
Ettinger A, Miklauz MM, Hendrix BK, Bihm DJ, Maldonado-Codina G, Goodrich RP. Quality of proteins in riboflavin and UV light-treated FFP during 1 year of storage at-18°C. Transfus Apher Sci 2012; 46(1): 15–18.
Ettinger A, Miklauz MM, Hendrix BK, Bihm DJ, Maldonado-Codina G, Goodrich RP. Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at-30°C. Transfus Apher Sci. 2011; 44(1): 25–31
Bihm DJ, Ettinger A, Buytaert-Hoefen KA, Hendrix BK, Maldonado-Codina G, Rock G, at al. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30°C. Vox Sang 2010; 98(2): 108–15.
Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46(7): 1168‒77.